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Abstract
Background: We studied the RNA expression of the genes in response to glucose from 5 mM
(condition of normoglycemia) to 20 mM (condition of hyperglycemia/diabetes) by microarray
analysis in breast cancer derived cell line MDA-MB-231. We identified the thioredoxin-interacting
protein (TXNIP), whose RNA level increased as a gene product particularly sensitive to the
variation of the level of glucose in culture media. We investigated the kinesis of the TXNIP RNA
and protein in response to glucose and the relationship between this protein and the related
thioredoxin (TRX) in regulating the level of reactive oxygen species (ROS) in MDA-MB-231 cells.
Methods: MDA-MB-231 cells were grown either in 5 or 20 mM glucose chronically prior to
plating. For glucose shift (5/20), cells were plated in 5 mM glucose and shifted to 20 mM at time 0.
Cells were analyzed with Affymetrix Human U133A microarray chip and gene expression profile
was obtained. Semi-quantitative RT-PCR and Western blot was used to validate the expression of
TXNIP RNA and protein in response to glucose, respectively. ROS were detected by CM-
H2DCFDA (5–6-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate) and measured for mean
fluorescence intensity with flow cytometry. TRX activity was assayed by the insulin disulfide
reducing assay.
Results: We found that the regulation of TXNIP gene expression by glucose in MDA-MB-231 cells
occurs rapidly within 6 h of its increased level (20 mM glucose) and persists through the duration
of the conditions of hyperglycemia. The increased level of TXNIP RNA is followed by increased
level of protein that is associated with increasing levels of ROS and reduced TRX activity. The
inhibition of the glucose transporter GLUT1 by phloretin notably reduces TXNIP RNA level and
the inhibition of the p38 MAP kinase activity by SB203580 reverses the effects of TXNIP on ROS-
TRX activity.
Conclusion: In this study we show that TXNIP is an oxidative stress responsive gene and its
expression is exquisitely regulated by glucose level in highly metastatic MDA-MB-231 cells.
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Background
We have recently described the gene expression profile
(GEP) of the highly metastatic breast cancer-derived
MDA-MB-231 cells in response to hyperglycemia in vitro
tissue culture [1]. Among all the RNAs that showed signif-
icant changes in response to increased level of glucose, the
level of RNA of the thioredoxin-interacting protein
(TXNIP), also known as vitamin D3 up-regulated protein-
1 (VDUP-1) was one of the most representatives [1].
The emphasis on the role of both insulin and insulin-like
growth factors 1 (IGF-1) or IGF binding proteins
(IGFBPs), together with the insulin-mediated regulation
of fat distribution, availability of sex hormone binding
globulin (SHBG), and sex hormones in the regulation of
proliferation and growth of breast derived cells, has
undermined the relevance of glucose by itself in breast
cancer [2-5]. In complex organisms such as vertebrates, it
becomes very difficult to discriminate glucose effects on
gene transcription from those related to either insulin or
glucagon, whose secretions are regulated by glucose [6].
However, the use of established cell lines has allowed
more recently the study of the direct effect of glucose on
the proliferation of hepatocytes [6].
It has been recently shown that the promoter region of the
TXNIP gene contains carbohydrate response elements
(ChoRE) conferring the described glucose responsiveness
in murine pancreatic β cells [7,8]. The function of TXNIP
as a modulator of the redox system through binding of the
thioredoxin (TRX) active cysteine residues has been eluci-
dated in recent studies [9,10]. The intracellular redox bal-
ance is maintained by reactive oxygen species (ROS)-
scavenger systems, mainly represented by the glutathione
and the TRX systems [11]. A recent study has also shown
that hyperglycemia causes oxidative stress through inhibi-
tion of TRX function by TXNIP in human aortic smooth
muscle cells [12].
In the current study, we initially validated the results of
the glucose-mediated expression of TXNIP obtained by
the initial GEP screening by assessing the levels of mRNA
by RT-PCR as compared to the level of TRX in breast can-
cer derived cell line MDA-MB-231 [1]. We then assessed
the time course of the variation of both RNA and protein
TXNIP levels in response to increased level of glucose, and
finally demonstrate that TXNIP regulates ROS levels
through TRX-activity in MDA-MB-231 cells.
Methods
Cell lines and tissue culture
Breast cancer-derived MDA-MB-231 cells were purchased
from American Type Culture Collection (Mannassas, VA).
Cells were grown to confluence in Dulbecco's modified
Eagle's medium (DMEM) plus 10% fetal calf serum (FCS)
containing 28 mM/L sodium bicarbonate, 10 mM/L
sodium pyruvate, 5 mM/L D-glucose, and 2 mM/L L-
glutamine at 37°C (pH 7.4). The cells were maintained in
5 or 20 mM/L D-glucose chronically prior to plating. For
glucose shift, cells were plated in 5 mM/L D-glucose and
shifted to 20 mM at time 0.
Semi-quantitative RT-PCR
Total RNA was isolated using Aquapure RNA isolation kit
(Bio-Rad, Hercules, CA) and first strand c-DNA synthesis
by iScript c-DNA amplification kit (Bio-Rad) according to
manufacture's protocol. Primers were designed with Bea-
con Designer program (Premier Biosoft, Palo Alto, CA) as
it follows: TXNIP SENSE 5'-TCA Tgg TgA Tgt TCA AgA AgA
TC-3'; ANTISENSE 5'-ACT TCA CAC CTC CAC TAT C-3';
TRX SENSE 5'-CAg ggg AAT gAA AgA AAg g-3'; ANTI-
SENSE 5'-CAA ggT gAA gCA gAT Cg-3'; β-ACTIN SENSE 5'-
TTT gAA TgA TgA gCC TTT gTg-3'; ANTISENSE 5'-TCA gTg
TAC Agg TAA gCC CT-3'. PCR products for TXNIP, TRX
and  β-actin were amplified using PCR-Supermix
(Promega, Madison, WI) using 1/10 of the cDNA reaction
mix with the following profile for 30 cycles: denaturation
95°C for 1 min, annealing 50° for 1 min and extension
68° for 1 min. PCR products were run by electrophoresis
on 3% agarose gel and stained with Syber-Sale DNA stain
(Invitrogen, Carlsbad, CA). For semi-quantization
amounts of RNA was estimated by the relative intensity
against the relative intensity of β-actin.
Inhibition of glucose transport
Cells (5 × 105) were plated in 6 well-dishes in duplicate in
5 mM glucose and allowed to attach overnight. Cells
receiving phloretin were pre-treated for 1 h prior to glu-
cose shift. At time 0, cells were either maintained in 5 mM
glucose or switched to 20 mM glucose + 300 µM phlore-
tin. Cells were harvested after 6 h for RNA isolation as pre-
viously described.
Western and immunoblot analysis
For analysis of chronic TXNIP protein expression cells
were maintained indefinitely in DMEM with 5 or 20 mM
glucose. For the time course of TXNIP protein level, cells
maintained in 5 mM glucose were plated in 6 well-plates.
At time 0, fresh medium containing 20 mM glucose was
added and cells were harvested at indicated time-points.
From cell lysates 100 µg of total proteins was run on 10%
SDS PAGE gel by electrophoresis and blotted with rabbit
polyclonal antibody to TXNIP (Invitrogen, Carlsbad, CA).
Blots were stripped and reprobed for β-actin (Labvison,
Fremont, CA) as loading control.
ROS assay, TRX activity, and p38 MAP kinase inhibition
ROS was detected by CM-H2DCFDA (5- [and -6]-chlo-
romethyl-2',7'-dichlorodihydrofluorescein diacetate,
acetyl ester (Molecular Probes). Cells were loaded with 10BMC Cancer 2007, 7:96 http://www.biomedcentral.com/1471-2407/7/96
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µM DCFDA for 30 min at 37°C, 5% CO2 in PBS. Cells
were washed and returned to media for a 30 min recovery
period. Mean fluorescence intensity was used as measure
of ROS as determined by flow cytometry FACS Calibur
using CellQuest Pro 5.2 on 1 × 104 cells (BD Bioscience,
San Jose, CA) [13]. TRX activity was assessed by the insu-
lin disulfide reducing assay as previously described [13].
Briefly, 50 µg of cell extract was incubated in reducing
buffer (50 mM HEPES, 1 mM EDTA, 1 mg/ml BSA and 2
mM DTT) at 37°C for 15 min. After the addition of reac-
tion buffer, the reaction was started by the addition of 5 µl
bovine thioredoxin reductase (100 U/ml) or water as neg-
ative control followed by 20 min incubation. The reaction
was stopped by the addition of 0.5 ml of stopping buffer
(6 M guanidine-HCl, and 1 mM DNTB). The absorbance
at 412 nm was measured. For p38 MAP kinase inhibition
experiments, 5 × 105 cells were initially seeded and main-
tained in 5 or 20 mM glucose media, and then the cells at
20 mM glucose were treated for 24 h with 20 µM specific
inhibitor SB203580 (Sigma, St Louis, MO).
Statistical analysis
Experiments were carried in duplicates or triplicates as
specified. Differences between treatments were evaluated
by ANOVA or student's t-test. Differences were accepted as
significant if p < 0.05 (two-tailed).
Results
Hyperglycemia regulates the levels of TXNIP RNA, but not 
of TRX RNA
Our GEP data were obtained from MDA-MB-231 cells
chronically maintained in media containing 5 or 20 mM
glucose prior to plating as previously described [1]. In
order to assess the "subacute" glucose shift, cells were
plated in 5 mM glucose and shifted to 20 mM at time 0
[1]. Cell viability and proliferation was assessed by trypan
blue exclusion at various time-points and when a signifi-
cant difference in growth (separation of the curves for
each cell group 5, 5/20 and 20 mM glucose) was seen at
12 h (data not shown and presented in Ref. 1) RNA was
harvested and hybridized to Affymetrix Human µ133A
chips as described in the Methods. GeneSpring 7.2 was
used to average results and perform analysis between
treatment groups [1]. Final profiles were generated using
minimum of 1.5 fold change function [1].
As shown in Figure 1A according to our GEP data, the level
of TXNIP increased from 1528 ± 637 in MDA-MB-231
cells grown in culture media containing 5 mM glucose to
4572 ± 765 when the cells were placed in 20 mM glucose.
Cells chronically grown in media containing 20 mM glu-
cose showed the highest level at 7104 ± 823, while the
TRX level remained unchanged with the increasing level
of glucose concentration (Figure 1A). To validate the GEP
data, we assessed the level of TXNIP and TRX message by
semi-quantitative RT-PCR and reported as relative level to
the control RNA β-actin. Relative levels of TXNIP
increased with increasing levels of glucose (0.21 ± 0.03 at
5 mM vs 0.72 ± 0.12 at 5/20 mM vs 0.95 ± 0.10 at 20 mM;
p < 0.05) resulting in an overall 4.3 fold increase from 5
mM to 20 mM (Figure 1B). On the contrary, TRX message
remained unchanged at the various glucose levels (Figure
1B). These results validated the GEP data confirming that
the level of TXNIP RNA significantly increased upon "sub-
acutely" increasing and persistently maintaining elevated
levels of glucose (chronic conditions), while TXR RNA
message remained unchanged.
Hyperglycemia acutely regulates the increase of TXNIP 
RNA level and is dependent on the cellular level of glucose
The level of TXNIP RNA in the initial GEP and in the val-
idating semi-quantitative RNA analysis were derived from
conditions of "chronic" or stable growth in 20 mM glu-
cose, and even in conditions of shifting from 5 to 20 mM
glucose, the measurements occurred after 12 h from the
shift (Figure 1). For the purpose of determining the earli-
est time after increasing the glucose concentration the rise
of the TXNIP RNA level took place, we investigated the
time course of RNA expression by semi-quantitative PCR
analysis. As shown in Figure 2, the TXNIP/β actin level
ratio significantly increased within 1 h and significantly (p
< 0.05) continued to increase up to 6 h (0.14 ± 0.02 at 0
h; 0.22 ± 0.02 at 1 h; 0.30 ± 0.02 at 3 h; 0.36 ± 0.03 at 6
TXNIP and TRX expression in response to glucose assessed  by gene expression profile (GEP) and semi-quantitative PCR Figure 1 
TXNIP and TRX expression in response to glucose 
assessed by gene expression profile (GEP) and semi-
quantitative PCR. A) MDA-MB-231 cells were grown 
either in 5 or 20 mM glucose chronically prior to plating. For 
glucose shift (5/20), cells were plated in 5 mM glucose and 
shifted to 20 mM at time 0. Cells were harvested at 12 h 
based on previous growth curves obtained at specified glu-
cose concentration and RNA was isolated, labeled and 
hybridized to Affymetrix Human U133A microarray chip. 
Average derived from duplictaes is shown as relative expres-
sion of TXNIP and TRX RNAs, respectively. B) TXNIP and 
TRX RNA message levels were detected by semi-quantitative 
PCR in MDA-MB-231 cells grown in the same conditions as 
in A. Average relative levels as compared to control β-actin 
RNA of TXNIP and TRX RNA messages from duplicates are 
represented. Representative gel electrophoresis of PCR 
products obtained from duplicate experiments is shown in 
the inset.BMC Cancer 2007, 7:96 http://www.biomedcentral.com/1471-2407/7/96
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h). These data show that the effect of glucose on TXNIP
RNA level is rapid and increases with exposure to high lev-
els of glucose (20 mM) within hours.
To assess whether the glucose-induced increase of TXNIP
RNA at 6 h was regulated by the intracellular level of glu-
cose, we inhibited the transport of the glucose with phlo-
retin which is an effective though not specific inhibitor of
the GLUT1 transporter as previously shown [14,15]. The
inhibitor significantly reduced the level of TXNIP RNA (5
mM vs 20 mM, p = 0.012; 20 mM vs 20 mM + phloretin,
p = 0.027; 5 mM vs 20 mM + phloretin, p = 0.002) as
shown in Figure 2B and expressed as ratio to control (0.30
± 0.01 at 5 mM; 1.00 ± 0.11 at 20 mM; 0.53 ± 0.01 at 20
mM + phloretin).
Hyperglycemia-mediated increase of TXNIP RNA 
correlates with TXNIP protein level
For the purpose of assessing whether the increased level of
TXNIP RNA determined by prolonged conditions of
hyperglycemia (20 mM, chronic conditions) were corre-
lated with correspondent elevated levels of TXNIP protein,
we analyzed the expression of the protein in MDA-MB-
231 cells grown "chronically" and stably in 20 mM glu-
cose tissue culture media by Western blot. As shown in
Figure 3A, the intensity of the band (expressed as ratio to
the reference β-actin protein) within the expected molec-
ular weight (50 kDa) of the TXNIP protein which was
absent at 5 mM notably increased in the cells grown at 20
mM glucose (0.02 ± 0.005 at 5 mM vs 1.08 ± 0.05 at 20
mM glucose). This finding showed that TXNIP protein
level correlated with RNA message and glucose level in
MDA-MB-231 cells.
In order to evaluate the earliest time of increasing levels of
TXNIP protein caused by the increasing levels of glucose
(acute conditions), we executed the time course/Western
blot analysis within hours from the switch 5/20 mM using
MDA-MB-231 cells chronically grown at 20 mM glucose
as control. As shown in Figure 3B the intensity of the band
(expressed as ratio to the reference β-actin protein) in the
expected MW range of TXNIP protein increased over the
time reaching a peak at 18 h (0.03 ± 0.001 at 0 h, 0.03 ±
0.01 at 6 h, 0.08 ± 0.02 at 12 h, 0.78 ± 0.09 at 18 h), which
occurred 12 h after the peak level of RNA message (Figure
2A). The peak level of TXNIP protein persisted at 24 h
(Figure 3B, ratio at 24 = 0.79 ± 0.03) confirming the fact
that TXNIP protein level remains persistently elevated if
the glucose level remains elevated at 20 mM as shown in
chronic conditions. These data confirm that hyperglyc-
TXNIP protein expression and time chase of the TXNIP pro- tein expression in response to glucose Figure 3 
TXNIP protein expression and time chase of the 
TXNIP protein expression in response to glucose. A) 
MDA-MB-231 cells were grown either in 5 or 20 mM glucose 
chronically prior to plating as described. Cells were har-
vested and total proteins obtained from cell lysates were run 
on 10% SDS PAGE gel by electrophoresis and blotted with 
rabbit polyclonal antibody to TXNIP. Blots were stripped 
and reprobed for β-actin as loading control to estimate the 
average ratio of band intensity from duplicates as shown. 
Representative Western blot obtained from 2 experiments is 
shown in the inset. B) MDA-MB-231 cells were chronically 
grown at 5 mM and then switched to 20 mM glucose at t = 0 
and treated as described. Cells were harvested at the time 
points indicated and total proteins obtained from cell lysates 
were run on 10% SDS PAGE gel by electrophoresis and blot-
ted with rabbit polyclonal antibody to TXNIP. Blots were 
stripped and reprobed for β-actin as loading control to esti-
mate the average ratio of band intensity from duplicates as 
shown. Representative Western blot obtained from 2 exper-
iments at each time point is shown in the inset.
Time course of the TXNIP RNA expression and response to  inhibition of glucose transporter Figure 2 
Time course of the TXNIP RNA expression and 
response to inhibition of glucose transporter. A) 
MDA-MB-231 cells were chronically grown at 5 mM and 
then switched to 20 mM glucose at t = 0. RNA was meas-
ured by semi-quantitative PCR at the indicated time points 
and shown as average ratio of control β-actin RNA levels 
derived from duplicates. Representative gel electrophoresis 
of PCR products obtained from 2 experiments is shown in 
the inset. B) Cells were grown chronically at 5 mM and then 
switched to 20 mM glucose at t = 0. RNA was measured by 
semi-quantitative PCR at 6 h and shown as average ratio of 
control β-actin RNA levels from duplicates. For inhibition of 
the glucose transporter study cells were pre-treated for 1 h 
with 300 µM phloretin. Representative gel electrophoresis of 
PCR products obtained from 2 experiments is shown in the 
inset.BMC Cancer 2007, 7:96 http://www.biomedcentral.com/1471-2407/7/96
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emia affects acutely and chronically RNA and protein lev-
els of TXNIP causing persistent elevated levels.
TXNIP/ROS/TRX axis is inversely related in conditions of 
hyperglycemia
It has been recently shown that TXNIP binds to TRX and
regulates the activity of this protein as a major cellular
redox regulator [9,10]. Furthermore, hyperglycemia has
also been shown to promote oxidative stress through inhi-
bition of TRX function by TXNIP in human aortic smooth
muscle cells (ASMCs) [12]. In order to assess whether
hyperglycemia exerted any action in regulating ROS as an
indicator of oxidative stress in response to 20 mM glucose
(hyperglycemia)-induced elevation of TXNIP RNA level,
we measured the ROS level as detected by CM-H2DCFDA
and expressed as percentage of mean fluorescence by flow
cytometry (Figure 4B, inlet) in relation to the level of
TXNIP RNA. As shown in Figure 4A, as expected TXNIP
RNA level expressed as ratio to control raised from base-
line significantly (0.74 ± 0.07 at 5 mM glucose to 1.81 ±
0.14 at 20 mM glucose; p < 0.05). The increase of TXNIP
RNA level was associated with 2.3 fold increase of ROS
level in 20 mM vs 5 mM glucose (Figure 4B, 38.5% ± 4.2
for 20 mM vs 16.5% ± 2.0 for 5 mM glucose; p < 0.05).
When we measured TRX activity, this decreased 1.6 fold
from 5 to 20 mM glucose (0.496 ± 0.06 for 5 mM vs 0.320
± 0.02 for 20 Mm glucose; p < 0.05) as shown in Figure
4C. Our data demonstrate that hyperglycemia-induced
TXNIP elevation is associated with decreased TRX activity
resulting in increasing levels of ROS in MDA-MB-231
cells.
Hyperglycemia-induced TXNIP-ROS activity is mediated 
through p38 MAP kinase
A recent study has demonstrated that hyperglycemia-
induced increased level of TXNIP is associated with activa-
tion of p38 MAP kinase in human ASMCs [12]. To assess
whether p38 MAP kinase signaling pathway affected
hyperglycemia-regulated TXNIP/TRX/ROS axis, we treated
MDA-MB-231 cells with 20 µM of the specific kinase
inhibitor SB203580. As illustrated in Figure 4A, TXNIP
RNA level significantly dropped from 1.81 ± 0.14 to 0.94
± 0.09 (p < 0.05) concordantly with the decreased ROS
level (Figure 4B, from 38.5 ± 0.4 to 11.8 ± 0.2; p < 0.05).
On the other hand, TRX activity significantly increased
with the inhibitor (Figure 4C, from 0.320 ± 0.02 to 0.581
± 0.04, p < 0.05). These data favor the functional rele-
vance of p38 MAP kinase in metastatic breast-cancer
derived cells MDA-MB-231 similarly to ASMCs as previ-
ously described [12].
Discussion
In this study, we show that the metabolic condition of
hyperglycemia affects the level of both TXNIP RNA and
protein in breast-cancer derived cells MDA-MB-231. Thus
ROS and TRX activity in response to glucose and p38 MAPK  inhibition Figure 4 
ROS and TRX activity in response to glucose and p38 
MAPK inhibition. A) TXNIP RNA message levels were 
detected by semi-quantitative PCR in MDA-MB-231 cells 
grown either in 5 or 20 mM glucose chronically prior to plat-
ing. Average relative levels as compared to control β-actin 
RNA of TXNIP and TRX RNA messages from triplicates are 
represented. For inhibition of the p38 MAP kinase cells 
grown at 20 mM were pre-treated for 24 h with 20 µM 
SB203580. B) MDA-MB-231 cells were grown either in 5 or 
20 mM glucose chronically prior to plating. Cells were 
assessed for ROS levels by DCFDA fluorescence staining and 
flow cytometry as shown in the inlet. For inhibition of the 
p38 MAP kinase cells grown at 20 mM glucose were treated 
for 24 h with 20 µM SB203580. Average mean fluorescence 
from triplicates is expressed per each group of cells. B) 
MDA-MB-231 cells were grown either in 5 or 20 mM glucose 
chronically prior to plating. Cells were assessed for TRX 
activity by the insulin disulfide reducing assay as described 
and the average OD 410 readings from triplicates are shown 
for each group of cells. For inhibition of the p38 MAP kinase 
cells grown at 20 mM were pre-treated for 24 h with 20 µM 
SB203580.BMC Cancer 2007, 7:96 http://www.biomedcentral.com/1471-2407/7/96
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the persistent elevation of TXNIP protein is strictly corre-
lated with the persistency of the elevation of the glucose
level and is very sensitive to its magnitude. In our cellular
model, we have reproduced the conditions of postpran-
dial hyperglycemia by shifting the glucose level from 5 to
20 mM and the conditions of insulin-resistant hyperglyc-
emia (diabetes) by maintaining the cells "chronically"
and stably at 20 mM glucose. We show that hyperglycemia
by itself has a major impact on both the level of TXNIP
and the regulation of ROS level/TRX activity in MDA-MB-
231 cells. The regulation of TXNIP RNA level is related to
the intracellular level of glucose and is notably reduced by
the inhibition of the glucose transport. In fact, the
increased uptake of glucose is relevant in regulating this
function as demonstrated by the inhibition of the glucose
transporter. Although phloretin did not completely
inhibit the glucose-effect, the compound notably reduced
TXNIP RNA. This observation may be explained by the
presence of other GLUT proteins responsible for the glu-
cose transport not inhibited by phloretin (e.g., compare 5
mM vs 20 mM in Figure 2B) as previously shown in breast
cancer-derived cells [16]. However, the statistically signif-
icant reduction of TXNIP RNA obtained with phloretin-
mediated inhibition of the major glucose transporter
GLUT1 present in MDA-MB-231 cells supports the rele-
vance of the intracellular glucose in the regulation of the
TXNIP expression in MDA-MB-231 cells.
These data validate GEP reported by us and others that
TXNIP represents a gene whose regulation is highly sensi-
tive to glucose levels in metastatic breast cancer-derived
MDA-MB-231 cells and in murine pancreatic β cells,
respectively [1,7]. We also show that the regulation of the
TXNIP/TRX/ROS axis is associated with p38 MAP kinase
signaling pathway. These data are in agreement with pre-
vious observations in different cell models [12,17]. How-
ever, considering that MDA-MB-231 cells may have an
increased baseline "hyperactive" MAP kinase activity due
to ras-oncogene protein family dysregulation, the func-
tional relevance of p38 MAP kinase in this and other
breast cancer-derived cell lines needs to be further
explored [18]. As shown herein, TXNIP-inhibiting TRX
activity is highly regulated by glucose, hitherto we suggest
that this protein may play a major role in translating the
biological consequences of a metabolic condition such as
diabetes in cancer biology. Recent studies have related the
effect of hyperglycemia to increased generation of ROS
and to greater DNA oxidative damage as main mechanism
of accelerated aging and atherogenesis in the microangio-
pathic complications of the disease [12,17,19]. Although
the relevance of diabetes in the pathogenesis and clinical
course of tumors in general and particularly of breast can-
cer has been controversially debated, we illustrate for the
first time in this context the molecular relationship
between hyperglycemia and increased ROS production in
a cancerous cellular model [2]. Our study opens new ave-
nues for the investigation of the consequences of the
described hyperglycemia-TXNIP-TRX-ROS axis on suscep-
tibility to oxidative stress in oncogenesis and tumor pro-
gression. Although it has been proven that exogenous
overexpression of TXNIP suppresses growth and induces
apoptosis in vascular smooth muscle cells and cardiomy-
ocytes, it has only been more recently that apoptosis and
"glucotoxicity" have been related through TXNIP in
murine pancreatic β cells [8,15]. However, in the current
exploratory study, we did not address the ultimate effect
of hyperglycemia-mediated TXNIP expression on apopto-
sis. Furthermore, it has been shown that glucose con-
sumption rate is lower in non-invasive MCF-7 cells versus
metastatic breast cancer-derived MDA-MB-231 cells used
in the current study [20]. Gatenby et al. showed that up-
regulation of glycolysis leads to microenvironmental aci-
dosis as an evolutionary mechanism for the metastatic cell
to adapt to the acidic microenvironment and promote
proliferation and invasion [20]. Although the adaptive
mechanism was well described, the question whether
hyperglycemia represents a favorable or unfavorable con-
dition for the cancerous cell that highly depends upon gly-
colysis was not posed [20]. Hitherto, future studies are
warranted to assess whether hyperglycemia-induced
TXNIP/TRX/ROS biology is a prerogative of MDA-MB-231
cells or it extends to other breast cancer-derived cell lines
independently from their hormonal receptor status (estro-
gen receptors) or signaling pathways (ras mutations, p38
MAKP milieu, etc.). Although various studies have
recently addressed the relevance of TXNIP in cancer biol-
ogy, our study is the first one relating this protein to met-
abolic conditions of hyperglycemia/diabetes and
oxidative stress in the same context [21-24]. Even though
the incompleteness of this exploratory work that was
meant to validate the preliminary findings of increased
level of TXNIP observed in GEP in response to hyperglyc-
emia hampers the understanding of the ultimate conse-
quence of increased ROS for the growth of tumor cells in
the metabolic conditions of hyperglycemia, we are confi-
dent that further investigative work will lead to the identi-
fication of the molecular mechanisms relating diabetes to
cancer.
Conclusion
Conclusively, we show that hyperglycemia finely regulates
the expression of TXNIP in breast-derived cancer cells
MDA-MB-231. The increased level of the protein leads to
increased ROS levels through TRX reduced activity that is
reversed by p38 MAP kinase inhibition. We describe an
important signaling pathway that might be involved in
diabetes-mediated oxidative stress in cancer. Our findings
support further investigation in this perspective.BMC Cancer 2007, 7:96 http://www.biomedcentral.com/1471-2407/7/96
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